A T-cell player with backing from Roche takes next big step for BiTE drugs with ‘on-off’ switch to avoid toxicity

The bispecific T cell engager field is absolutely packed with big-name players who have crowded in despite some high-profile failures in the class. Now, a Bay Area biotech thinks it may have the key to tackling BiTE toxicity, using an old “on-off switch” idea to give doctors more control of...

Click to view original post